MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Alkermes plc Long-Term Debt 2011-2026 | ALKS
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Alkermes plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.3 M | 69.4 M | 288 M | 290 M | 293 M | 272 M | 274 M | 276 M | 278 M | 281 M | 284 M | 349 M | 362 M | 441 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 441 M | 63.3 M | 273 M |
Quarterly Long-Term Debt Alkermes plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.2 M | 67.8 M | 69.4 M | 286 M | 286 M | 287 M | 288 M | 288 M | 289 M | 290 M | 290 M | 291 M | - | 292 M | 293 M | 293 M | 294 M | 295 M | 272 M | 272 M | 272 M | 272 M | 274 M | 274 M | 274 M | 274 M | 276 M | 276 M | 276 M | 276 M | 278 M | 278 M | 278 M | 278 M | 281 M | 281 M | 281 M | 281 M | 284 M | 284 M | 284 M | 284 M | 349 M | 351 M | 351 M | 351 M | 358 M | 358 M | 358 M | 358 M | 362 M | 364 M | 441 M | 441 M | 442 M | 442 M | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 442 M | 66.2 M | 296 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
806 K | $ 4.5 | 0.45 % | $ 862 M |  Canada |
 |
ADC Therapeutics SA
ADCT
|
6.99 M | $ 3.83 | 1.32 % | $ 105 M |  Schweiz |
 |
Agenus
AGEN
|
30.5 M | $ 3.64 | 9.31 % | $ 108 M |  USA |
 |
Agios Pharmaceuticals
AGIO
|
21.8 M | $ 35.08 | -0.36 % | $ 2.03 B | USA |
 |
Akebia Therapeutics
AKBA
|
48.2 M | $ 1.39 | 0.36 % | $ 357 M | USA |
 |
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
173 M | - | 2.54 % | $ 160 B |  France |
 |
Aldeyra Therapeutics
ALDX
|
15 M | $ 1.57 | -5.42 % | $ 94.3 M | USA |
 |
Aligos Therapeutics
ALGS
|
122 K | $ 8.08 | 1.38 % | $ 79.9 M | USA |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | France |
 |
Alnylam Pharmaceuticals
ALNY
|
1.01 B | $ 331.14 | 3.85 % | $ 43.4 B | USA |
 |
Altimmune
ALT
|
34.3 M | $ 3.4 | 1.8 % | $ 300 M | USA |
 |
ALX Oncology Holdings
ALXO
|
4.53 M | $ 1.99 | 0.81 % | $ 107 M | USA |
 |
Amgen
AMGN
|
50 B | $ 344.03 | -1.12 % | $ 185 B | USA |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
2.57 B | $ 12.27 | -1.68 % | $ 3.85 B | USA |
 |
Anika Therapeutics
ANIK
|
26.9 M | $ 14.99 | 1.28 % | $ 220 M | USA |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
309 M | $ 73.8 | -0.55 % | $ 1.43 B | USA |
 |
Annexon
ANNX
|
23.3 M | $ 5.56 | 1.0 % | $ 862 M | USA |
 |
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aptorum Group Limited
APM
|
130 K | $ 0.88 | -5.16 % | $ 4.8 M | China |
 |
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | USA |
 |
Aquestive Therapeutics
AQST
|
45 M | $ 4.12 | -0.24 % | $ 441 M | USA |
 |
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
2.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
20.8 M | $ 8.14 | 1.31 % | $ 223 M |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
Ardelyx
ARDX
|
203 M | $ 5.99 | 0.84 % | $ 1.44 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
108 M | $ 24.06 | 1.82 % | $ 3.06 B | USA |
 |
Arvinas
ARVN
|
400 K | $ 10.87 | 0.14 % | $ 771 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
104 M | $ 60.28 | -1.23 % | $ 8.06 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
210 K | - | 3.16 % | $ 1.9 M | USA |
 |
Assembly Biosciences
ASMB
|
2.06 M | $ 29.51 | 1.72 % | $ 331 M | USA |
 |
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
69 K | - | 10.36 % | $ 9.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
59.9 K | $ 3.62 | 1.82 % | $ 8.71 B |  Australia |